QUECTEL-WIRELESS
25.7.2024 11:22:35 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the LG290P, the first quad-band GNSS module, designed to deliver high performance for the most demanding applications, ensuring exceptional RTK availability and quality even in challenging environments. Providing the instantaneous centimeter-level accuracy needed to ensure the precision required for applications such as precision agriculture, robotic lawn mowers, surveying and personal robots, the module also delivers superior coverage that supports base stations from greater distances, ensuring reliable performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725061807/en/
Quectel unveils industry-first quad-band GNSS module, expanding comprehensive GNSS solutions portfolio (Photo: Business Wire)
The introduction of the LG290P module expands Quectel's range of high-accuracy, RTK-capable GNSS modules. This range includes the dual-band industrial-grade LC29H, the automotive-grade LG69T, and now the quad-band LG290P, providing users with a selection of GNSS modules to cover a wide variety of applications.
Future-proofing applications by supporting all constellations including GPS, GLONASS, Galileo, BDS, NavIC, QZSS, as well as SBAS support (WASS, EGNOS, MSAS, and GAGAN) and advanced satellite-based signals such as PPP-B2b, CLAS (QZSS L6), Galileo HAS E6, the LG290P is a cost-effective industrial-grade module that receives L1, L2, L5 and E6 frequency bands.
In addition, the LG290P is compatible with Quectel triple band RTK Services and ensures superior coverage that supports base stations from greater distances, ensuring stable and reliable performance in the most difficult urban environments, making it exceptionally well suited for sectors such as autonomous lawnmowers, delivery robots, surveying and precision agriculture. The quad-band solution can enhance the RTK fix rate by 50% compared to dual band in extremely challenging environments, such as a garden encircled by trees and walls. Additionally, it can reduce the time to achieve RTK fix to less than five seconds, in contrast to the ten to fifteen seconds required by the dual band solution.
“Introducing the quad-band GNSS Module to the market represents our commitment to advancing technology and providing our customers with the most reliable and accurate navigation solutions available,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We believe this product will be a game-changer in many fields, enabling new possibilities and improving efficiencies and precise location.”
The module supports an advanced multi-frequency RTK algorithm, ensuring rapid and reliable RTK high-precision positioning results even in challenging conditions such as under dense tree cover, alongside buildings or inside urban canyons. With advanced anti-interference technology, the LG290P incorporates a professional-grade interference signal detection and Narrowband Interference Canceller (NIC), significantly enhancing signal reception performance in complex electromagnetic environments. Moreover, supporting integrity monitoring and authentication information verification, the LG290P aids automatic navigation systems in making control decisions, particularly fitting for critical applications like autonomous vehicles and lawnmowers.
The LG290P excels in terms of security by incorporating on-chip ECC check and Secure Boot for firmware protection. Measuring a compact 12.2 mm × 16.0 mm × 2.6 mm, the LG290P is the smallest quad-band module available, offering greater design flexibility for customers, reducing integration challenges, and enabling compact designs for a wide array of precision products.
Customers are also able to streamline their design process by sourcing the appropriate antenna for this module, ensuring flexibility and compatibility for diverse project requirements.
The LG290P quad band GNSS module is now available to order through the Quectel website and distributors.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725061807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom